Summary: In this level-1 study, 2 Phase III randomized, double-blind, placebo-controlled studies (ULTRA I in the U.S. and ULTRA II in Germany) evaluated the safety and efficacy of incobotulinumtoxinA for simultaneous treatment of moderate-to-severe upper facial lines—glabellar frown lines, horizontal forehead lines, and lateral canthal lines. Participants received up to 64 units of incobotulinumtoxinA or placebo, with treatment success defined by a ≥2-grade improvement on the Merz Aesthetics Scale. In both trials, incobotulinumtoxinA showed significantly greater efficacy than placebo across all endpoints (P < .0001), with consistent results in open-label extension periods and no new safety concerns.

This article contains supplemental material located online at
https://doi.org/10.1093/asj/sj...

Vladimir Sudimac MD

Appearances